More promising evidence comes from the use of the (1-3)IGF1 analog, NNZ-2566 (Trofinetide) as a treatment for FXS; in fact mouse models of FXS treated with NNZ-2566 showed improvements in cognitive function and hyperactivity. The gene discussed is IGF1; the disease is fragile X syndrome.